Investing

Insiders Are Loving These 6 Stocks Right Now

VTT Studio / iStock via Getty Images
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly. That is a challenge for investors and portfolio managers trying to position themselves for 2025. The most notable insider purchases in the past week were in the following six stocks. They included a couple of biotech and a couple of energy companies, as well as a specialty retailer. Let’s take a quick look at these transactions.

24/7 Wall St. Key Points:

  • Insiders are among those investors positioning themselves for the coming year.
  • The most notable insider purchases in the past week were in biotech and energy companies, as well as a specialty retailer.
  • Take this quiz to see if you’re on track to retire. (sponsored)

Is Insider Buying Important?

frender / iStock via Getty Images
What does insider buying tell us?

A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a company because they believe the stock price will rise and they want to profit from it. Thus, insider buying can be an encouraging signal for potential investors. This is all the more so during times of uncertainty in the markets, and even when markets are near all-time highs.

The earnings-reporting season has wound down, so fewer insiders are prohibited from buying or selling shares. Below are some of the more notable insider purchases that were reported in the past week, starting with the largest and most prominent.

Revolution Medicines

Ridofranz / iStock via Getty Images
A public offering of shares tempts an insider.
  • Buyer(s): a director
  • Total shares: around 1.3 million
  • Price per share: $46.00
  • Total cost: about $60.0 billion

The director took advantage of a public offering of Revolution Medicines Inc. (NASDAQ: RVMD) shares. This Redwood City-based oncology company’s stock popped after the most recent quarterly report but has pulled back since the secondary offering was announced. Shares were last seen trading for a little less than the purchase price above. The share price is still about 83% higher than a year ago, far outperforming the broader markets. Analysts see plenty more room to run, as their consensus price target is up at $73 per share. All 15 analysts who follow the stock recommend buying shares, five of them with Strong Buy ratings.

AlTi Global

utah778 / iStock via Getty Images
Who is buying the dip?
  • Buyer(s): 10% owner Tiedemann Advisors
  • Total shares: more than 1.9 million
  • Price per share: $10.05 to $10.13
  • Total cost: about $19.5 million

This buyer has boosted its AlTi Global Inc. (NASDAQ: ALTI) stake to almost 6.5 million shares. Shares of the New York City-based wealth and asset manager are up about 21% since the most recent quarterly report. However, the stock is down around 49% since the beginning of the year. Only one analyst covers the stock, and that analyst’s $9 price target suggests that the share price could double in the coming year. Note that AlTi was formerly known as Alvarium Tiedemann Holdings and changed its name in April 2023.

Aurinia Pharmaceuticals

luchschen / Getty Images
Who is buying into a restructuring biotech?
  • Buyer(s): a director
  • Total shares: 1.2 million
  • Price per share: $8.74 to $9.19
  • Total cost: over $10.8 million

After trimming its workforce early in the year, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) recently had further layoffs as it restructured to tighten its focus on its primary lupus nephritis treatment and accelerate the development of a preclinical asset for autoimmune diseases. This Canadian biotech’s share price is greater than the purchase price range above and over 71% higher than six months ago. Based on the current mean price target of $10.84, the stock has upside of nearly 15% in the coming 12 months. Analysts on average recommend buying shares.

Shoe Carnival

summerphotos / iStock via Getty Images
A stock with plenty of room to run?
  • Buyer(s): Board Chair J. Wayne Weaver
  • Total shares: 285,500
  • Price per share: $33.91
  • Total cost: almost $9.7 million

Shoe Carnival Inc. (NASDAQ: SCVL) just declared its 51st consecutive quarterly dividend and announced a new share repurchase program for up to $50 million. Shares were last seen trading for about the same as the purchase price above. The stock is up over 22% from a year ago, which is shy of the performance of the S&P 500. The $49.00 consensus price target indicates that Wall Street sees more than 45% upside potential for the coming year. Analysts on average recommend buying shares. Note that Weaver has a stake of almost 4.2 million shares, making him a beneficial owner.

Mach Natural Resources

GoodLifeStudio / E+ via Getty Images
A director buys the dip.
  • Buyer(s): a director
  • Total shares: less than 363,800
  • Price per share: $14.61 to $15.25
  • Total cost: around $5.0 million

Anadarko Basin-focused independent upstream oil and gas company Mach Natural Resources L.P. (NYSE: MNR) recently completed two acquisitions and raised $129 million in a public offering. The share price is almost 9% lower than a year ago, much of that retreat coming after the announcement of the offering. But shares were last seen still within the purchase price range above. The $23.25 consensus price target indicates that analysts see plenty of room to run in the next 52 weeks. All four analysts who cover the stock recommend buying shares. Trust Securities initiated its coverage last week.

PBF Energy

zorazhuang / E+ via Getty Images
A beneficial owner and return buyer.
  • Buyer(s): 10% owner Control Empresarial de Capitales
  • Total shares: 137,000
  • Price per share: $29.87 to $30.01
  • Total cost: about $4.1 million

This Carlos Slim-controlled investment firm has been scooping up shares of PBF Energy Inc. (NYSE: PBF) since early June. Now its stake is up to around 28.0 million shares. The New Jersey-based refiner posted mixed quarterly results and hiked its dividend at the end of October. The stock has been in retreat since early April, hit a new 52-week low last month, and was last seen trading for less than the buyer’s latest purchase price range. Analysts have a mean price target of $31.23, which represents over 6% upside potential in the next 12 months. Yet, none of the 15 analysts who follow the stock recommends acquiring shares.

And Other Insider Buying

Chris Hondros / Getty Images
Some smaller insider buys at Johnson & Johnson, Norfolk Southern, and more.

In the past week, some insider buying was reported at American Homes 4 Rent, APA, Booz Allen Hamilton, Bowlero, Dave & Buster’s, FS KKR Capital, Hormel Foods, Hubbell, Illinois Tool Works, Johnson & Johnson, Matador Resources, MSCI, Norfolk Southern, and SAIC as well.

Stock Splits Matter: Here’s What’s Coming in December

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.